PATENT
Docket No.: **20011/1262**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Michael Peter Trova	Examiner: To Be Assigned
Serial No.	:	Continuation of 09/950,543	
Cnfrm. No.	:	To Be Assigned	Art Unit: To Be Assigned
Filed	:	Herewith	
For	:	NITROGEN SUBSTITUTED BIARYL PURINE DERIVATIVES AS POTENT ANTIPROLIFERATIVE AGENTS	

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97-1.98

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicant hereby brings to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

Pursuant to 37 CFR § 1.98(d), references identified with reference numbers 1-5, 7-9, and 11-31 on the attached PTO-1449 form are not provided, because these references either were previously cited by or submitted to the PTO in parent U.S. Patent Application Serial No. 09/950,543, filed September 11, 2001, of which this application claims priority under 35 U.S.C. §120. References 6 and 10 are attached hereto.

Respectfully submitted,

Date: October 5, 2003

Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	Continuation of 09/950,543
Filing Date	Herewith
First Named Inventor	Trova
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	20011/1262

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number - Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5,282,824	02/01/1994	Gianturco	
	2	US-5,866,702	02/02/1999	Mackman et al.	
	3	US-6,316,456	11/13/2001	Meijer et al.	
	4	US-6,413,974	07/02/2002	Dumont et al.	
	5	US-6,479,487	11/12/2002	Dumont et al.	
	6	US-6,627,633	09/30/2003	Trova	
	7	US-2002/0035252	03/21/2002	Lum et al.	
	8	US-2002/0032327	03/14/2002	Lum et al.	
	9	US-2002/0091263 A1	07/11/2002	Trova	
	10	US-2003/0092909	05/15/2003	Trova	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	11	WO 99/43676	09/02/1999			
	12	WO 98/05335	02/12/1998			
	13	WO 99/43675	09/02/1999			
	14	FR 2 741 881 A	06/06/1997			
	15	WO 99/07705	02/18/1999			
	16	WO 00/55161	09/21/2000			
	17	FR 2 793 794 A1	11/24/2000			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	18	Schow et al., "Synthesis and Activity of 2,6,9-Trisubstituted Purines," Bioorganic & Medicinal Chemistry Letters 7(210):2697-2703 (1997)	
	19	Imbach et al., "2,6,9-Trisubstituted Purines: Optimization Towards Highly Potent and Selective CDK1 Inhibitors," Bioorganic & Medicinal Chemistry Letters 9:91-96 (1999)	
	20	Legraverend et al., "Synthesis and *in vitro* Evaluation of Novel 2,6,9-Trisubstituted Purines Acting as Cyclin-Dependent Kinase Inhibitors," Bioorganic & Medicinal Chemistry 7:1281-1293 (1999)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	Continuation of 09/950,543
Filing Date	Herewith
First Named Inventor	Trova
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	20011/1262

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	U.S. Patent Document Number - Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] Number[4] Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	21	Pérez-Roger et al., "Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases," Current Pharmaceutical Biotechnology, 1:107-116 (2000)	
	22	Gray et al., "ATP-Site Directed Inhibitors of Cyclin-Dependent Kinases," Current Medicinal Chemistry, 6:859-875 (1999)	
	23	Brooks et al., "The Cell Cycle and Drug Discovery: The Promise and the Hope," DDT, 4(10):455-464 (1999)	
	24	Coleman et al., "Chemical Inhibitors of Cyclin-Dependent Kinases," in Plattner, ed., Annual Reports in Medicinal Chemistry, Academic Press, Inc., 32:171-179 (1997)	
	25	Mani et al., "Cyclin-Dependent Kinase Inhibitors: Novel Anticancer Agents," Exp. Opin. Invest. Drugs, 9(8):1849-1870 (2000)	
	26	Fischer et al., "Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics," Current Medicinal Chemistry, 7:1213-1245 (2000)	
	27	Stedman, Stedman's Medical Dictionary, 26th Ed., Williams & Wilkins, Baltimore, Maryland, pp. 1534, 1673 (1995)	
	28	Mattsson et al., "Current Concepts in Restenosis Following Balloon Angioplasty," Trends Cardiovasc. Med., 5(5):200-204 (1995)	
	29	Nikol et al., "Regulation of Smooth Muscle Cell Proliferation and its Possible Role in Preventing Restenosis Post- Angioplasty," Wien Klin Wochenschr, 107(13):379-389 (1995)	
	30	American Heart Association "Stenosis and Restenosis of Coronary Arteries," http://americanheartassociation.com/ Heart_and_Stroke_A_Z_Guide/sten.html (2001)	
	31	Green et al., Protective Groups in Organic Synthesis (Second Edition), pgs. 318-319 and 331-332 (1991)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.